LipimetiX Development, LLC   Report issue

For profit Phase 2
Founded: Natick MA United States (2012)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2014
NCT02100839
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

aem-28 (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypercholesterolemia (Phase 2)

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2